Advances in treating peritoneal oligometastasis in gastric cancer

Peritoneal metastasis from gastric cancer significantly impacts prognosis, but advancements in diagnostic and therapeutic strategies are transforming patient outcomes. A peritoneal cancer index (PCI) threshold of ≤6 identifies patients with oligometastasis who may benefit from aggressive therapies. Cytoreductive surgery coupled with hyperthermic intraperitoneal chemotherapy remains essential for curative intent. Emerging techniques like normothermic and pressurized intraperitoneal aerosol chemotherapy are broadening treatment options, emphasizing individualized approaches for improved survival rates in previously challenging cases.